Regeneron Pharmaceuticals, Inc. (REGN)
NASDAQ · Health Care · market cap 64.45B
Share price
$789.45
At the last nightly close
Intrinsic value
$823.95
Range $823.95 – $986.78 — the conservative figure is the low end.
Margin of safety
+4.4%
($823.95 − $789.45) ÷ $789.45
EV / EBIT
38.6
On the median operating profit of 15 fiscal years through 2025.
How these numbers are computed
The valuations are calculated in Python from filed accounts, not written by a language model. Three methods run side by side: earnings power value, which capitalises a normalised operating profit; a free-cash-flow model; and the Graham Number as an asset-side cross-check. The conservative figure above is the low end of what they agree on.
The frame gives no credit for growth. A company that compounds will therefore read as expensive against it — that is deliberate. It is a price-discipline floor, not a price target, and it is not a view on what the shares will do.
The EV/EBIT ranking uses the median operating profit of up to fifteen fiscal years — a full cycle — where the free screeners use the last twelve months. When the data cannot support a method, the figure reads n/a rather than a number: a free-cash-flow valuation on a bank, a PEG on erratic earnings, a multiple on a company with no operating profit to speak of.
Fundamentals from SEC EDGAR. Prices, market data and technicals from yfinance. Valuation computed 2026-09-03.
Key metrics
Market position
Annual financials
| Period | Revenue | Operating income | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|
| 2025-FY | 14.34B | 3.70B | 4.50B | 43.07 | 3.77B |
| 2024-FY | 14.20B | 3.99B | 4.41B | 40.90 | 3.54B |
| 2023-FY | 13.12B | 4.05B | 3.95B | 37.05 | 3.67B |
| 2022-FY | 12.17B | 4.74B | 4.34B | 40.51 | 3.40B |
| 2021-FY | 16.07B | 8.95B | 8.08B | 71.97 | 6.53B |
Filed figures from SEC EDGAR, in the reporting currency.
Next earnings
Recent news
- Regeneron Pharmaceuticals (REGN) Advances +28% in ...tickeron.com
- Regeneron Pharmaceuticals (REGN) Earnings Date and Reports 2026marketbeat.com
- Regeneron Pharmaceuticals Inc. Stock , REGN - Markets Insidermarkets.businessinsider.com
- Surging Earnings Estimates Signal Upside for Regeneron (REGN) Stockfinance.yahoo.com
- Regeneron Pharmaceuticals, Inc. (REGN) Stock Price, News, Quote & History - Yahoo Financefinance.yahoo.com
Headlines link to their source. Sperio does not republish article text.
The figures above are the arithmetic. To see what a board of eight AI agents makes of them — macro, sector, filings, news and a devil's advocate whose only job is to attack the thesis — run the full analysis on REGN.
Run the board on REGN10 free analyses · no signup, no card
This page presents computed figures and filed financial data for information only. It is not investment advice, not a recommendation to buy or sell any security, and not a statement about what these shares will do. Sperio is a research tool, not an investment adviser. Figures are derived automatically from public filings and market data and may be incomplete, out of date or wrong. See the Terms & Disclaimer.